Verrica Pharmaceuticals Inc (VRCA) Stock Price, Quote & News

Company Profile

Verrica Pharmaceuticals Inc., a dermatology therapeutics company, engages in the development and commercialization of medications for the treatment of dermatologic diseases in the United States. The company offers YCANTH (VP-102) a drug-device combination that contains a GMP-controlled formulation of cantharidin for the treatment of molluscum in adult and pediatric patients, as well as for the treatment of common warts. It also develops VP-315, an oncolytic peptide-based injectable therapy that...

Industry: Biotechnology

Sector: Healthcare

Phone: 484 453 3300

Website: www.verrica.com

Address:

44 West Gay Street, Suite 400, West Chester, United States

t_lamp3 May. 13 at 8:44 PM

$VRCA Everyone’s focused on YCANTH revenue… meanwhile the real lottery ticket is VP-315. A potential injectable alternative to cutting basal cell carcinomas off. Phase 2 showed: • 51% complete histologic clearance • 97% response rate • Minimal systemic exposure If Phase 3 hits, this isn’t just another derm company anymore. Feels like the market still thinks VRCA is a molluscum-only story. https://verrica.com/press_release/verrica-pharmaceuticals-presents-new-data-on-vp-315-from-its-phase-2-clinical-trial-in-basal-cell-carcinoma-at-the-40th-society-for-immunotherapy-of-cancer-annual-meeting/

0 · Reply

captain5500 May. 13 at 5:29 PM

$VRCA strong rev growth

0 · Reply

MarketBeat May. 13 at 3:09 AM

https://marketbeat.com/a/8651239/ $VRCA Verrica Pharmaceuticals Q1 Earnings Call Highlights

0 · Reply

EarningsInsider May. 12 at 9:32 PM

https://www.marketbeat.com/earnings/reports/2026-5-12-verrica-pharmaceuticals-inc-stock/ $VRCA Verrica Pharmaceuticals Earnings Transcript

0 · Reply

BioGem May. 12 at 9:29 PM

$VRCA I have mentioned their dismal performance for the past 6 months, and not sure why investors still bought it, all while they diluted by double the number of shares not too long ago. -Adoption of the product in the USA is too weak and slow, despite a big expansion in their sales team. -Their losses are deepening. -Cash burn is too heavy and unsustainable. -Cash is already critically low. -Add several millions in pre-funded warrant already vested. -I expect another round of dilution imminently.

0 · Reply

Merlintrader May. 12 at 8:21 PM

$VRCA Verrica Pharmaceuticals (Nasdaq: $VRCA): Q1 2026 earnings show stronger YCANTH demand, lower debt burden and a still-tight cash clock https://www.merlintrader.com/verrica-pharmaceuticals-deepdive-april2026/

0 · Reply

StocktwitsEarnings May. 12 at 8:12 PM

$VRCA Q1 '26 Earnings Results & Recap • Reported GAAP EPS of -$0.45 up 55.00% YoY • Reported revenue of $5.02M up 46.06% YoY

0 · Reply

GOLDENSAFEBETS May. 6 at 10:13 PM

$VRCA 👀

1 · Reply

Merlintrader May. 5 at 8:39 PM

$VRCA Verrica Pharmaceuticals: VP-315 Phase 2 Data Put a Fresh Spotlight on Basal Cell Carcinoma https://www.merlintrader.com/verrica-pharmaceuticals-may2026-update/

0 · Reply

PatrickandFrankie Apr. 30 at 12:39 PM

$VRCA whats up ? Any news in premarket?

0 · Reply

Verrica Pharmaceuticals to Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ

2026-05-12T21:57:53.000Z - 2 days ago

Verrica Pharmaceuticals reports Q1 adjusted EPS (41c), consensus (59c)

May 12, 2026, 4:30 PM EDT - 2 days ago

Verrica Pharmaceuticals Earnings Call Transcript: Q1 2026

May 12, 2026, 4:01 PM EDT - 2 days ago

Verrica Pharmaceuticals Reports First Quarter 2026 Financial Results

May 5, 2026, 4:05 PM EDT - 9 days ago

Verrica Pharmaceuticals Announces Upcoming Presentation of Phase 2 Data Highlighting the Potential Abscopal Effects of VP-315 in the Treatment of Basal Cell Carcinoma at the 2026 Society for Investigative Dermatology (SID) Annual Meeting

SID

May 5, 2026, 8:00 AM EDT - 9 days ago

Verrica Pharmaceuticals to Report First Quarter 2026 Financial Results and Provide a Corporate Update on May 12, 2026

Apr 15, 2026, 3:00 PM EDT - 4 weeks ago

Verrica Pharmaceuticals Transcript: 25th Annual Needham Virtual Healthcare Conference

Apr 9, 2026, 4:05 PM EDT - 5 weeks ago

Verrica Pharmaceuticals Announces Acceptance of Late-Breaking Abstract Highlighting Potential Abscopal Effect of VP-315 for the Treatment of Basal Cell Carcinoma at the Upcoming 2026 Society for Investigative Dermatology Annual Meeting

Apr 6, 2026, 8:00 AM EDT - 5 weeks ago

Verrica Pharmaceuticals to Participate in the 25th Annual Needham Virtual Healthcare Conference

Mar 11, 2026, 8:30 AM EDT - 2 months ago

Verrica Pharmaceuticals Earnings Call Transcript: Q4 2025

2026-03-11T12:06:44.000Z - 2 months ago

Verrica Pharmaceuticals reports Q4 adjusted EPS (51c), consensus (79c)

Mar 11, 2026, 8:00 AM EDT - 2 months ago

Verrica Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results

Mar 5, 2026, 8:00 AM EST - 2 months ago

Verrica Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results and Provide a Corporate Update on March 11, 2026

Mar 2, 2026, 10:30 AM EST - 2 months ago

Verrica Pharmaceuticals Transcript: TD Cowen 46th Annual Health Care Conference

Feb 23, 2026, 8:00 AM EST - 2 months ago

Verrica Pharmaceuticals to Participate in the TD Cowen 46th Annual Health Care Conference

2026-02-12T13:11:17.000Z - 3 months ago

Verrica Pharmaceuticals appoints Chapman as Chief Commercial Officer

Feb 12, 2026, 8:00 AM EST - 3 months ago

Verrica Pharmaceuticals Appoints Chris Chapman as Chief Commercial Officer

2026-02-09T13:20:47.000Z - 3 months ago

Verrica Pharmaceuticals Launches Ycanth for treatment of Molluscum in Japan

Feb 9, 2026, 8:00 AM EST - 3 months ago

Verrica Pharmaceuticals Announces Launch of YCANTH® for the Treatment of Molluscum Contagiosum in Japan by Partner Torii Pharmaceutical

2026-01-07T13:16:25.000Z - 4 months ago

Verrica announces first patient dosed in program evaluating YCANTH

Jan 7, 2026, 8:00 AM EST - 4 months ago

Verrica Pharmaceuticals Announces First Patient Dosed in Phase 3 Program Evaluating YCANTH® (VP-102) for the Treatment of Common Warts

2025-12-18T02:10:17.000Z - 5 months ago

Verrica Pharmaceuticals upgraded to Buy from Hold at Brookline

2025-12-15T21:25:42.000Z - 5 months ago

Verrica Pharmaceuticals files to sell 14.76M shares of common stock for holders

2025-11-24T13:11:05.000Z - 6 months ago

Verrica Pharmaceuticals announces private placement financing of $50M

Nov 24, 2025, 8:00 AM EST - 6 months ago

Verrica Pharmaceuticals Announces Private Placement Financing of $50 Million to Retire Debt and Extend Cash Runway

Nov 17, 2025, 8:30 AM EST - 6 months ago

Verrica Pharmaceuticals Earnings Call Transcript: Q3 2025

2025-11-14T21:10:36.000Z - 6 months ago

Verrica Pharmaceuticals reports Q3 adjusted EPS 13c, consensus (84c)

Nov 14, 2025, 4:05 PM EST - 6 months ago

Verrica Pharmaceuticals Reports Third Quarter 2025 Financial Results

2025-11-10T13:15:34.000Z - 6 months ago

Verrica Pharmaceuticals presents new data on VP-315 from Phase 2 trial

Nov 10, 2025, 8:00 AM EST - 6 months ago

Verrica Pharmaceuticals Presents New Data on VP-315 from its Phase 2 Clinical Trial in Basal Cell Carcinoma at the 40th Society for Immunotherapy of Cancer Annual Meeting

2025-11-05T11:46:01.000Z - 6 months ago

Verrica Pharmaceuticals initiated with a Buy at Lucid Capital

Oct 24, 2025, 11:00 AM EDT - 7 months ago

Halper Sadeh LLC Encourages Verrica Pharmaceuticals, Inc. Shareholders to Contact the Firm to Discuss Their Rights

2025-10-20T20:45:12.000Z - 7 months ago

Verrica Pharmaceuticals announces CHMP support for Ycanth MAA filing

Oct 20, 2025, 4:05 PM EDT - 7 months ago

Verrica Pharmaceuticals Receives Positive Feedback from the European Medicines Agency (EMA) Supporting a Clear Regulatory Path Forward to File for Approval of YCANTH® in the European Union

Oct 7, 2025, 4:05 PM EDT - 7 months ago

Verrica Pharmaceuticals to Present New Data on VP-315 from its Phase 2 Trial in Basal Cell Carcinoma (BCC) at the 40th Society for Immunotherapy of Cancer (SITC) Annual Meeting

2025-09-19T12:05:32.000Z - 8 months ago

Verrica Pharmaceuticals development partner receives approval for YCANTH

Sep 19, 2025, 8:00 AM EDT - 8 months ago

Verrica Pharmaceuticals Announces That Development Partner, Torii Pharmaceutical, Receives Approval for YCANTH® (TO-208) in Japan for the Treatment of Molluscum Contagiosum

Sep 8, 2025, 9:30 AM EDT - 8 months ago

Verrica Pharmaceuticals Transcript: H.C. Wainwright 27th Annual Global Investment Conference

Sep 2, 2025, 7:00 AM EDT - 9 months ago

Verrica Pharmaceuticals to Participate in the H.C. Wainwright 27th Annual Global Investment Conference

Aug 12, 2025, 4:30 PM EDT - 9 months ago

Verrica Pharmaceuticals Earnings Call Transcript: Q2 2025

Aug 12, 2025, 4:01 PM EDT - 9 months ago

Verrica Pharmaceuticals Reports Second Quarter 2025 Financial Results

Aug 6, 2025, 7:00 AM EDT - 10 months ago

Verrica Pharmaceuticals to Report Second Quarter 2025 Financial Results and Provide a Corporate Update on August 12, 2025

2025-07-09T11:15:25.000Z - 11 months ago

Verrica reports 13,434 YCANTH dispensed applicator units in Q2

Jul 9, 2025, 7:00 AM EDT - 11 months ago

Verrica Pharmaceuticals Reports Strong Growth in YCANTH® Dispensed Applicator Units in 2Q 2025

2025-07-01T11:16:21.000Z - 11 months ago

Verrica announces amendment to collab, license agreement with Torri

Jul 1, 2025, 7:00 AM EDT - 11 months ago

Verrica Pharmaceuticals Announces Amendment to Collaboration and License Agreement with Torii Pharmaceutical to Launch Global Pivotal Phase 3 Clinical Trial to Study YCANTH® for the Treatment of Common Warts

Jun 4, 2025, 4:20 PM EDT - 1 year ago

Verrica Pharmaceuticals Transcript: Jefferies Global Healthcare Conference 2025

May 28, 2025, 8:00 AM EDT - 1 year ago

Verrica Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference in New York

May 13, 2025, 4:30 PM EDT - 1 year ago

Verrica Pharmaceuticals Earnings Call Transcript: Q1 2025

2025-05-13T20:18:39.000Z - 1 year ago

Verrica Pharmaceuticals reports Q1 EPS (10c), consensus (14c)

May 13, 2025, 4:05 PM EDT - 1 year ago

Verrica Pharmaceuticals Reports Quarterly 2025 Financial Results

May 7, 2025, 3:00 PM EDT - 1 year ago

Verrica Pharmaceuticals Transcript: The Citizens JMP Life Sciences Conference 2025

May 7, 2025, 8:00 AM EDT - 1 year ago

Verrica Pharmaceuticals to Report First Quarter 2025 Financial Results and Provide a Corporate Update on May 13, 2025

Apr 30, 2025, 8:00 AM EDT - 1 year ago

Verrica Pharmaceuticals to Participate in the Citizens Life Sciences Conference in New York

Apr 8, 2025, 1:30 PM EDT - 1 year ago

Verrica Pharmaceuticals Transcript: 24th Annual Needham Virtual Healthcare Conference

2025-04-07T12:15:57.000Z - 1 year ago

Verrica Pharmaceuticals experiences ‘strong demand-led growth’ for YCANTH in Q1

Apr 2, 2025, 4:05 PM EDT - 1 year ago

Verrica Pharmaceuticals Appoints Gavin Corcoran, M.D. to its Board of Directors

Mar 31, 2025, 8:00 AM EDT - 1 year ago

Verrica Pharmaceuticals to Participate in the 24th Annual Needham Virtual Healthcare Conference

2025-03-26T11:10:46.000Z - 1 year ago

Verrica Pharmaceuticals appoints Rosenberg as CMO

Mar 26, 2025, 7:00 AM EDT - 1 year ago

Verrica Pharmaceuticals Appoints Noah L. Rosenberg, M.D.

Mar 11, 2025, 4:30 PM EDT - 1 year ago

Verrica Pharmaceuticals Earnings Call Transcript: Q4 2024

Mar 11, 2025, 4:05 PM EDT - 1 year ago

Verrica Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results

Mar 3, 2025, 2:30 PM EST - 1 year ago

Verrica Pharmaceuticals Transcript: TD Cowen 45th Annual Healthcare Conference

Mar 3, 2025, 7:00 AM EST - 1 year ago

Verrica Pharmaceuticals to Report Fourth Quarter and Full Year 2024 Financial Results and Provide a Corporate Update on March 11, 2025

Feb 25, 2025, 4:05 PM EST - 1 year ago

Verrica Pharmaceuticals to Participate in the TD Cowen 45th Annual Health Care Conference in Boston

Dec 9, 2024, 4:15 PM EST - 1 year ago

Verrica Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Dec 6, 2024, 8:00 AM EST - 1 year ago

Verrica Pharmaceuticals Announces that Development Partner Torii Pharmaceutical Files New Drug Application of TO-208 the Treatment of Molluscum Contagiosum in Japan

Nov 21, 2024, 7:30 AM EST - 1 year ago

Verrica Announces Pricing of $42.0 Million Public Offering

Nov 20, 2024, 4:05 PM EST - 1 year ago

Verrica Announces Proposed Public Offering

Oct 30, 2024, 10:00 AM EDT - 1 year ago

Verrica Pharmaceuticals Inc. Investor Alert (NASDAQ: VRCA): Schubert Jonckheer & Kolbe LLP Investigating Potential Shareholder Claims Against the Company's Officers and Directors for Possible False Statements

Oct 24, 2024, 7:00 AM EDT - 1 year ago

Verrica Pharmaceuticals Announces Acceptance of Two Abstracts Featuring Positive Preliminary Topline Results of VP-315 for the Treatment of Basal Cell Carcinoma at the 2024 Fall Clinical Dermatology Conference

Oct 11, 2024, 5:21 PM EDT - 1 year ago

VERRICA PHARMACEUTICALS INVESTIGATION CONTINUED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of Verrica Pharmaceuticals Inc. - VRCA

Oct 2, 2024, 7:30 AM EDT - 1 year ago

Verrica Pharmaceuticals Announces Restructuring of Commercial Organization

Sep 27, 2024, 10:29 PM EDT - 1 year ago

VERRICA PHARMACEUTICALS INVESTIGATION CONTINUED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of Verrica Pharmaceuticals Inc. - VRCA

Sep 9, 2024, 1:30 PM EDT - 1 year ago

Verrica Pharmaceuticals Transcript: H.C. Wainwright 26th Annual Global Investment Conference 2024

Sep 4, 2024, 7:30 AM EDT - 1 year ago

Verrica Pharmaceuticals to Participate in the H.C. Wainwright 26th Annual Global Investment Conference in New York

Aug 14, 2024, 8:30 AM EDT - 1 year ago

Verrica Pharmaceuticals Earnings Call Transcript: Q2 2024

Aug 14, 2024, 7:45 AM EDT - 1 year ago

Verrica Pharmaceuticals Reports Second Quarter 2024 Financial Results

Aug 14, 2024, 7:30 AM EDT - 1 year ago

Verrica Pharmaceuticals Announces Positive Preliminary Topline Results from Part 2 of Phase 2 Clinical Study of VP-315, an Investigational Oncolytic Peptide-Based Immunotherapy for the Treatment of Patients with Basal Cell Carcinoma

Aug 6, 2024, 7:30 AM EDT - 1 year ago

Verrica Pharmaceuticals to Report Second Quarter Financial Results and Release Preliminary Topline Results from Part 2 of Phase 2 Trial of VP-315 for the Treatment of Basal Cell Carcinoma on August 14, 2024

t_lamp3 May. 13 at 8:44 PM

0 · Reply

captain5500 May. 13 at 5:29 PM

$VRCA strong rev growth

0 · Reply

MarketBeat May. 13 at 3:09 AM

https://marketbeat.com/a/8651239/ $VRCA Verrica Pharmaceuticals Q1 Earnings Call Highlights

0 · Reply

EarningsInsider May. 12 at 9:32 PM

https://www.marketbeat.com/earnings/reports/2026-5-12-verrica-pharmaceuticals-inc-stock/ $VRCA Verrica Pharmaceuticals Earnings Transcript

0 · Reply

BioGem May. 12 at 9:29 PM

0 · Reply

Merlintrader May. 12 at 8:21 PM

0 · Reply

StocktwitsEarnings May. 12 at 8:12 PM

$VRCA Q1 '26 Earnings Results & Recap • Reported GAAP EPS of -$0.45 up 55.00% YoY • Reported revenue of $5.02M up 46.06% YoY

0 · Reply

GOLDENSAFEBETS May. 6 at 10:13 PM

$VRCA 👀

1 · Reply

Merlintrader May. 5 at 8:39 PM

$VRCA Verrica Pharmaceuticals: VP-315 Phase 2 Data Put a Fresh Spotlight on Basal Cell Carcinoma https://www.merlintrader.com/verrica-pharmaceuticals-may2026-update/

0 · Reply

PatrickandFrankie Apr. 30 at 12:39 PM

$VRCA whats up ? Any news in premarket?

0 · Reply

Merlintrader Apr. 13 at 3:36 PM

$VRCA

0 · Reply

Merlintrader Apr. 10 at 1:34 PM

$VRCA Verrica Pharmaceuticals ( $VRCA): deep dive 2026 after the balance-sheet reset, the YCANTH ramp and the renewed VP-315 scientific story https://www.merlintrader.com/verrica-pharmaceuticals-deepdive-april2026/

0 · Reply

focafoca99 Apr. 9 at 9:11 PM

$VRCA said a late-breaking abstract on VP-315 was accepted for SID 2026, with the company highlighting a potential abscopal effect in basal cell carcinoma.

0 · Reply

SuperGreenToday Apr. 9 at 2:52 AM

$VRCA

0 · Reply

focafoca99 Apr. 6 at 6:31 PM

$VRCA is just promoting participation in the Needham healthcare conference.

0 · Reply

SkullInferno Mar. 30 at 6:08 PM

$VRCA

0 · Reply

BioGem Mar. 14 at 11:53 PM

$VRCA Shortable above 6$. Including the additional vested pre-funded warrants, they have near 21.5M shares outstanding, and the mkt cap of 130M. Too expensive with many critical negatives: -No growth QOQ of product revenue. Means adoption is poor. Generics and new at-home options are ruthless competition. -Deep operating and bottom-line losses to deepen through 2026 (expansion of sales and marketing and launching new trials). -Much lower accounts receivable and higher current liabilities now, mean a big cash burn in Q1 26. -Cash will run out before year end = Another very dilutive offering will be required.

1 · Reply

prismmarketview Mar. 12 at 1:33 PM

We've added Verrica Pharmaceuticals (NASDAQ: $VRCA) to the PRISM Pharmaceuticals Index, spotlighting its focused work in dermatology and specialty care. YCANTH is gaining solid early commercial traction, with strong 2025 revenue growth reflecting increasing adoption for molluscum contagiosum. The pipeline continues to advance meaningfully: a global Phase 3 program for common warts is underway following the first patient dosing late last year, and VP-315 is progressing in development as a potential non-surgical option for basal cell carcinoma. This addition underscores Verrica's commitment to addressing unmet needs in skin disease treatments. @VerricaPharma #Pharmaceuticals https://prismmarketview.com/companies/verrica-pharmaceuticals-inc/

0 · Reply

mikesterz7 Mar. 11 at 12:50 PM

$VRCA Brookline Capital Acquisition upgraded shares of Verrica Pharmaceuticals from a "hold" rating to a "buy" rating and set a $17.00 target price.

0 · Reply

OpenOutcrier Mar. 11 at 12:49 PM

$VRCA (-10.0% pre) VRCA: Revenue growth and cost controls narrowed losses, but liquidity risks persist https://ooc.bz/l/96291

0 · Reply

StocktwitsEarnings Mar. 11 at 12:15 PM

$VRCA Q4 '25 Earnings Results & Recap • Reported GAAP EPS of -$0.57 up 76.35% YoY • Reported revenue of $5.09M up 1380.23% YoY • Verrica Pharmaceuticals Inc. believes its $30.1M cash as of December 31, 2025, is sufficient until Q1 2027, but substantial doubt exists about its ability to continue as a going concern for one year without additional funding.

0 · Reply

ash1012 Mar. 9 at 2:04 PM

$VRCA get in now going to double this week

0 · Reply

Market Cap	126.61M
Revenue (ttm)	35.58M
Net Income (ttm)	-17.89M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-50.28%
Debt to Equity Ratio	0.00

Volume	82,200
Avg Vol	113,224
Day's Range	N/A - N/A
Shares Out	17.18M
Stochastic %K	33%
Beta	1.54
Analysts	Strong Sell
Price Target	$16.50